-
Igama eligcwele:Inhlanganisela Yokuvikela Umzimba-157, ai-pentadecapeptide (15-amino acid peptide)ekuqaleni behlukanisiwe nejusi yesisu somuntu.
-
Ukulandelana kwe-amino acid:I-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, isisindo samangqamuzana ≈ 1419.55 Da.
-
Uma iqhathaniswa namanye ama-peptide amaningi, i-BPC-157 izinzile emanzini nasejusi yesisu, okwenza ukuphatha ngomlomo noma kwesisu kube nokwenzeka.
Izindlela Zokwenza
-
I-Angiogenesis / Ukubuyiselwa Kwegazi
-
IyaphakamisaI-VEGFR-2ukubonakaliswa, ukukhuthaza ukwakheka kwemithambo yegazi emisha.
-
Ivula i-Indlela ye-Src-Caveolin-1-eNOS, okuholela ekukhululweni kwe-nitric oxide (NO), i-vasodilation, nokusebenza okuthuthukisiwe kwe-vascular.
-
-
I-Anti-inflammatory & Antioxidant
-
Yehlisa i-pro-inflammatory cytokines njengeI-IL-6futhiI-TNF-α.
-
Yehlisa ukukhiqizwa kwezinhlobo ze-oxygen esebenzayo (ROS), ivikela amaseli ekucindezelekeni kwe-oxidative.
-
-
Ukulungisa Izicubu
-
Ithuthukisa ukululama kwesakhiwo nokusebenza kumamodeli we-tendon, ligament, kanye nokulimala kwemisipha.
-
Ihlinzeka nge-neuroprotection kumamodeli okulimala kwesistimu yezinzwa emaphakathi (ukucindezelwa komgogodla, ukuphindaphinda kwe-ischemia yobuchopho), ukunciphisa ukufa kwe-neuronal kanye nokuthuthukisa ukululama kwemoto/izinzwa.
-
-
Ukulawulwa Kwethoni Yemithambo
-
Izifundo ze-Ex vivo ze-vascular zibonisa i-BPC-157 induces vasorelaxation, kuncike ku-endothelium eqinile kanye ne-NO izindlela.
-
Idatha yokuqhathanisa yezilwane ne-In Vitro
| Uhlobo Lokuhlola | Imodeli / Ukungenelela | Umthamo / Ukuphatha | Lawula | Imiphumela Ebalulekile | Idatha yokuqhathanisa |
|---|---|---|---|---|---|
| I-Vasodilation (i-rat aorta, i-ex vivo) | Phenylephrine-precontracted aortic izindandatho | BPC-157 kuze kube100 μg/ml | Ayikho i-BPC-157 | I-Vasorelaxation ~37.6 ± 5.7% | Kwehliselwe ku10.0 ± 5.1% / 12.3 ± 2.3%nge-NOS inhibitor (L-NAME) noma CHA scavenger (Hb) |
| I-Endothelial cell assay (HUVEC) | HUVEC isiko | 1 μg/ml | Ukulawula okungalashwa | ↑ AKUKHO ukukhiqizwa (1.35-ukuphinda); ↑ ukufuduka kweseli | Ukufuduka kuqedwe nge-Hb |
| Imodeli yesitho se-Ischemic (igundane) | I-ischemia engapheli | 10 μg/kg/ngosuku (ip) | Akukho ukwelashwa | Ukululama ngokushesha kokugeleza kwegazi, ↑ angiogenesis | Ukwelashwa > Lawula |
| Ukucindezelwa komgogodla (igundane) | Ukucindezelwa komgogodla we-Sacrococcygeal | Umjovo we-ip eyodwa imizuzu eyi-10 ngemuva kokulimala | Iqembu elingalashwa | Ukubuyiselwa okubalulekile kwezinzwa nesakhiwo | Iqembu lokulawula lahlala likhubazekile |
| Imodeli ye-Hepatotoxicity (CCl₄ / utshwala) | Ukulimala kwesibindi okudalwe ngamakhemikhali | 1 µg noma 10 ng/kg (ip / ngomlomo) | Angelashiwe | ↓ I-AST/ALT, i-necrosis encishisiwe | Iqembu lokulawula libonise ukulimala okukhulu kwesibindi |
| Izifundo zobuthi | Amagundane, onogwaja, izinja | Imithamo / imizila eminingi | Izilawuli ze-placebo | Abukho ubuthi obubalulekile, akukho LD₅₀ ephawuliwe | Kubekezelelwe kahle ngisho nangemithamo ephezulu |
Izifundo Zabantu
-
Case series: Umjovo we-Intra-articular we-BPC-157 kuziguli ze-12 ezinezinhlungu zamadolo → i-11 ibike ukukhululeka kobuhlungu obukhulu. Imikhawulo: alikho iqembu lokulawula, akukho ukuphuphuthekisa, imiphumela eqondile.
-
Ukuhlolwa komtholampilo: Ucwaningo lweSigaba I sokuphepha kanye ne-pharmacokinetic (NCT02637284) kumavolontiya anempilo angama-42 lwenziwa, kodwa imiphumela ayikashicilelwa.
Okwamanje,azikho izivivinyo ezilawulwa ngokungahleliwe ezisezingeni eliphakeme (RCTs)ziyatholakala ukuze kuqinisekiswe ukusebenza kahle komtholampilo nokuphepha.
Ukuphepha Nezingozi Ezingenzeka
-
I-Angiogenesis: Kunosizo ekwelapheni, kodwa ngokwethiyori kungakhuthaza i-tumor vascularization, isheshise ukukhula noma i-metastasis ezigulini ezinomdlavuza.
-
Umthamo & Ukuphatha: Isebenza kahle ezilwaneni ngemithamo ephansi kakhulu (ng–µg/kg), kodwa umthamo ophelele womuntu kanye nomzila kuhlala kungachaziwe.
-
Ukusetshenziswa isikhathi eside: Ayikho idatha egcwele yobuthi yesikhathi eside; izifundo eziningi ezesikhashana.
-
Isimo sokulawula: Ayigunyazwanga njengomuthi emazweni amaningi; ihlukaniswe ngokuthi ainto enqatshelweyi-WADA (I-World Anti-Doping Agency).
Imibono Eqhathanisekayo Nemikhawulo
| Ukuqhathanisa | Amandla | Ukulinganiselwa |
|---|---|---|
| Isilwane vs Umuntu | Imiphumela enenzuzo engaguquki ezilwaneni (i-tendon, nerve, ukulungiswa kwesibindi, i-angiogenesis) | Ubufakazi bomuntu buncane, abulawuleki, futhi abunakho ukulandelelwa kwesikhathi eside |
| Ibanga lomthamo | Isebenza ngemithamo ephansi kakhulu ezilwaneni (ng–µg/kg; µg/ml in vitro) | Umthamo womuntu ophephile/osebenzayo akwaziwa |
| Ukuqala kwesenzo | Ukuphathwa kwangaphambi kokulimala ngemuva kokulimala (isb, imizuzu eyi-10 ngemuva kokulimala komgogodla) kuveza ukululama okuqinile | Ukuba nokwenzeka ngokomtholampilo kwesikhathi esinjalo akucaci |
| Ubuthi | Awukho umthamo obulalayo noma imiphumela emibi kakhulu ebonwa ezinhlobonhlobo zezilwane eziningi | Ubuthi besikhathi eside, i-carcinogenicity, nokuphepha kokuzala kuhlala kungahloliwe |
Isiphetho
-
I-BPC-157 ibonisa imiphumela enamandla yokuvuselela nokuvikela kumamodeli ezilwane namaseliI-angiogenesis, i-anti-inflammation, ukulungiswa kwezicubu, i-neuroprotection, ne-hepatoprotection.
-
Ubufakazi bomuntu bulinganiselwe kakhulu, ngaphandle kwedatha yesilingo somtholampilo esiqinile etholakalayo.
-
Ngokuqhubekayoizilingo ezilawulwa ngokungahleliwe eziklanywe kahleziyadingeka ukuze kutholwe ukusebenza kahle, ukuphepha, umthamo olungile, kanye nemizila yokuphatha kubantu.
Isikhathi sokuthumela: Sep-23-2025